Mapping Pathways is a multi-national project to develop and nurture a research-driven, community-led global understanding of the emerging evidence base around the adoption of antiretroviral-based prevention strategies to end the HIV/AIDS epidemic. The evidence base is more than results from clinical trials - it must include stakeholder and community perspectives as well.

17 July 2012

Online Coverage of AIDS 2012 Kicks Off With Live Webcast On Sunday, July 22

via Kaiser Family Foundation

In partnership with the International AIDS Society, the Kaiser Family Foundation is the official webcaster of the XIX International AIDS Conference (AIDS 2012) – the premier gathering for those working in the field of HIV, as well as policy makers, persons living with HIV and other individuals committed to ending the pandemic. 

Kaiser will provide online access to the daily developments that take place at the conference in Washington, D.C. beginning this Sunday, July 22.

Tune in to the live webcast of the Opening Session on Sunday, July 22 at 19:00 (7 p.m. ET).  The Closing Session will also be webcast live on Friday, July 27 at 15:15 (3:15 p.m. ET).  Throughout the conference, Kaiser will provide webcasts, podcasts (in English and Spanish) and transcripts of roughly 50 other conference sessions. 

Additionally, on Friday, July 19, the Foundation and the Black AIDS Institute will present a webcast featuring leading conference speakers discussing expectations of the conference and on July 27, they’ll take a look at what was accomplished at AIDS 2012, what still needs to be done and begin to look ahead to AIDS 2014.

Kaiser's AIDS 2012 conference coverage, including live webcasts, will be available at www.kff.org/aids2012.  Visit the page now to see a guide to conference coverage.

GET THE WEBCAST & HEADLINES WIDGET

If your organization is interested in making the conference coverage available to its constituency, grab this free widget (pictured to the left) and place it on your website, blog or social networks. During the week of the conference, the widget will automatically update to display the latest available webcasts and news headlines.See the widget on the conference website. Get the widget here.  RSS feeds will also be available.

GET THE DAILY EMAIL

To follow news from the conference and be alerted each day with a list of available webcasts, sign up for the Kaiser Daily Global Health Policy Report, which will feature special conference coverage.

Kaiser’s coverage of AIDS 2012 will include:

• Live and tape-delayed webcasts and transcripts of each day's sessions, including the opening and closing sessions, all plenary sessions, and selected other sessions and press conferences;
• English- and Spanish-language audio podcasts of select sessions;
• Interviews with conference newsmakers, scientists and journalists; and
• Extended news coverage in the Kaiser Daily Global Health Policy Report, including summaries of coverage from international news sources and newly-released studies.

Check out the live webcast here.



[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

16 July 2012

FDA approves first drug for reducing the risk of sexually acquired HIV infection

via FDA

FDA News Release:

Today, the U.S. Food and Drug Administration approved Truvada (emtricitabine/tenofovir disoproxil fumarate), the first drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection and who may engage in sexual activity with HIV-infected partners. Truvada, taken daily, is to be used for pre-exposure prophylaxis (PrEP) in combination with safer sex practices to reduce the risk of sexually-acquired HIV infection in adults at high risk.

The FDA previously approved Truvada to be used in combination with other antiretroviral agents for the treatment of HIV-infected adults and children 12 years or older.

As part of PrEP, HIV-uninfected individuals who are at high risk will take Truvada daily to lower their chances of becoming infected with HIV should they be exposed to the virus. A PrEP indication means Truvada is approved for use as part of a comprehensive HIV prevention strategy that includes other prevention methods, such as safe sex practices, risk reduction counseling, and regular HIV testing.

"Today’s approval marks an important milestone in our fight against HIV," said FDA Commissioner Margaret A. Hamburg, M.D. "Every year, about 50,000 U.S. adults and adolescents are diagnosed with HIV infection, despite the availability of prevention methods and strategies to educate, test, and care for people living with the disease. New treatments as well as prevention methods are needed to fight the HIV epidemic in this country."

Read the rest here.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

NEJM Publishes Papers on PrEP

Last week, The New England Journal of Medicine published online papers on the Partners ("Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women"), FEM-PrEP ("Preexposure Prophylaxis for HIV Infection among African Women") and TDF2 ("Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana") studies.

There was also an editorial "Preexposure prophylaxis for HIV - Where Do We Go From Here," and a look at some interesting case vignetttes - would YOU prescribe PrEP in these circumstances?.

These are great resources, hope you check them out.

[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

13 July 2012

An AIDS-Free Generation?

via Science, by Salim S. Abdool Karim

The HIV pandemic remains a great global health challenge.  With an estimated 3.3 million people living with HIV today, is there really hope of achieving the vision of an AIDS-free generation? Optimists argue that strong political will and generous funding are the essential elements. But skeptics point to the deep-seated structural inadequacies in many health care systems, especially in Africa, where the need is greatest.

However, both sides agree that a potential combination of therapeutic and prophylactic antiretroviral strategies brings the prospect of HIV control within reach. And this month, the International AIDS Conference in Washington, DC, “Turning the Tide Together,” will attempt to galvanize concerted global action to focus the world’s attention on this challenge.

Knowledge of HIV status is the common gateway to both treatment and prevention. But many people remain unaware of their HIV status. Denial, stigma, and a lack of understanding of vulnerability and risk lead to low rates of HIV testing, suboptimal condom use, and poor rates of circumcision. In addition to wider HIV testing, scale-up of ART therapy, both for the patient’s benefit and for the prevention benefi t to partners,will be key to reducing HIV transmission and to reaching zero new HIV infections.

Read the rest.

(This article requires you to sign up for a free registration to access to the full text)


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

12 July 2012

'Treatment As Prevention' Rises As Cry In HIV Fight

via NPR, by Richard Knox
Kenya Jackson promises his community health worker he will stay on his HIV medication — to keep himself well, and to avoid infecting anyone else.AIDS researchers, policymakers and advocates are increasingly convinced that treating HIV is one of the best ways of preventing its spread.

The rallying cry is "treatment as prevention," and it's the overarching theme of this month's International AIDS Conference in Washington, D.C.

The idea is that identifying people infected with HIV and getting them in effective treatment as soon as possible not only prevents them from getting sick but almost eliminates the risk they'll pass the virus on to others.

Last summer a big study showed that people with HIV are 96 percent less likely to pass the virus on if they faithfully take antiviral medicine. Momentum behind treatment-as-prevention has grown since then.

This is a big change. For a long time in the world of HIV and AIDS, the conventional wisdom has been to delay treatment until people show signs of damage to their immune system. Partly this is because the drugs have side effects (although some are now easier to take), and partly because few people thought medical treatment itself could slow the spread of HIV.

"After many years of frustration, it is a transformational moment in the course of this epidemic," says Kevin Cranston, head of infectious disease control at the Massachusetts Department of Public Health. "Universal treatment can in fact result in an epidemic that looks to be petering out."

Read the rest.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]